Abstract: The invention is directed to novel compositions and methods for modulating inflammatory and/or immune responses. Such novel compositions are derived from extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as extraembryonic HLA-G positive or “EHP” cells) and Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells), alone or in combination with each other and/or in combination with various matrices and/or devices and/or other suitable active agents. The novel methods of modulating inflammatory and/or immune responses utilize such novel compositions.

Abstract: The invention is directed to a novel wound healing device. In particular, the invention is directed to a novel wound healing device comprising a suture or knitted mesh that has adsorbed onto it novel cellular factor-containing compositions (referred to herein as CFC), including Amnion-derived Cellular Cytokine Solution (referred to herein as ACCS) or Physiologic Cytokine Solutions (herein referred to as PCS), as well as methods of making and uses thereof.

Abstract: The invention is directed to immortalized cell compositions and compositions derived therefrom. The invention is further directed to methods of making and using such immortalized cell compositions and compositions derived therefrom. Such immortalized cell compositions include but are not limited to Immortalized Amnion-derived Multipotent Progenitor cells (herein referred to as I-AMP cells) and conditioned media derived therefrom (herein referred to as I-Amnion-derived Cellular Cytokine Solution or I-ACCS).

Abstract: The invention is directed to a novel wound healing device. In particular, the invention is directed to a novel wound healing device comprising a suture or knitted mesh that has adsorbed onto it novel cellular factor-containing compositions (referred to herein as CFC), including Amnion-derived Cellular Cytokine Solution (referred to herein as ACCS) or Physiologic Cytokine Solutions (herein referred to as PCS), as well as methods of making and uses thereof.

Abstract: Methods for preventing, reversing, ameliorating or treating dental diseases, disorders or injuries are provided. In particular, methods for preventing, reversing, ameliorating or treating dental diseases of the gingival (gums) and bone are provided. Such methods utilize novel compositions including, but not limited to, extraembryonic cytokine-secreting cells (herein referred to as ECS cells), including, but not limited to, Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as Amnion-derived Cellular Cytokine Solution or ACCS), and Physiologic Cytokine Solution (herein referred to as PCS), each alone or in combination with each other and/or other agents.

Abstract: The invention is directed to methods of modulating ischemic injury in tissues and organs. The invention is further directed to methods of increasing time to ischemic injury in tissues and organs. Such methods utilize compositions comprising cells capable of modulating inflammatory responses, referred to herein as Inflammatory Response Modulating Cells (IRMCs). The IRMCs any be used directly or cell membranes derived from them may be used in practicing the methods of the invention. In addition, the IRMCs and IRMC membranes may be used alone or in combination with each other and/or in combination with various suitable active agents.

Abstract: A medium supplement which promotes the secretion of tPA from cells producing this protein natively or by virtue of recombinant transformation without the concomitant addition of contaminating proteins is described. Autoclaved brain/heart infusion preparations contribute virtually no extraneous proteins to the medium but greatly enhance the secretion of tPA.

Abstract: A device which serves as an artificial pancreas comprises a hollow fiber which is surrounded by islets of Langerhans enclosed in a housing. The islets are suspended in a semi-gel matrix or supporting material that is sufficiently viscous to physically support and maintain location of the islets about the hollow fiber, but sufficiently fluid to enable removal of the islet suspension from the device, followed by reseeding or replacement with fresh islet suspension. The matrix in which the islets are suspended preferably comprises calcium sodium alginate. The semi-gel supporting material also enables long term maintenance of islet cells in in vitro culture.

Abstract: Disclosed is a method of improving protein production in protein-producing cell cultures. The method comprises the steps of culturing protein-producing cells in a medium comprising essential nutrients, vitamins, salts and amino acids, modified by the addition of increased amounts of amino acids so that the osmolarity of the medium is hypertonic, i.e., above about 340 milliosmoles, preferably within the range of 340 to 450 milliosmoles and most preferably 360 milliosmoles. Cells grown in such media produce protein at levels on the order of four times the protein production in normal, isotonic media.